Article

Bilateral treatment for mild-to-moderate hyperopia promising

Washington, DC &#8212 Good near and distance visual acuity may be achieved in mild-to-moderate hyperopia in patients using a bilateral treatment approach, reported Marguerite B. McDonald, MD, who spoke at a refractive symposium on hyperopia, conductive keratoplasty (CK, Refractec), and LASIK during the American Society of Cataract and Refractive Surgery annual meeting.

April 19 - Washington, DC - Good near and distance visual acuity may be achieved in mild-to-moderate hyperopia in patients using a bilateral treatment approach, reported Marguerite B. McDonald, MD, who spoke at a refractive symposium on hyperopia, conductive keratoplasty (CK, Refractec), and LASIK during the American Society of Cataract and Refractive Surgery annual meeting.

Dr. McDonald, clinical professor of ophthalmology, Tulane University School of Medicine, New Orleans, presented the results of a small retrospective case series in which patients with hyperopia were treated with CK for distance in one eye and hyperopic LASEK for near in the other eye with the VISX STAR S4 excimer laser.

The advantage of CK, a thermokeratoplasty technique used to reshape the cornea, is that it is less invasive than LASIK and can increase multifocality without the loss of contrast sensitivity, Dr. McDonald explained.

"Larger corrections are possible with CK," she continued. "It has less impact on dry eye than LASIK. There are no concerns regarding exposure in these small deep-set, hyperopic eyes. Useful vision returns within 3 to 5 days."

In this series of 16 patients, the preoperative mean uncorrected visual acuity in the CK eyes for distance was 20/50 (range, 20/20 to 20/80). At 3 months postoperatively, the UCVA for distance in the CK eyes was 20/20 or better in 70% of the eyes and 20/40 or better in 90%, she noted.

The near acuity in the CK eyes corrected for distance improved from J12 to J3 at 3 months postoperatively. In addition, there was no increase in cylinder in these eyes. In fact, 63% had no cylinder and 78% had less than 0.5 D of cylinder.

"There was a statistically significant change in higher-order aberrations (HOA) at 1 month. Everything returned to baseline at 3 months, except for spherical aberrations, which had a statistically significant improvement at 3 months," Dr. McDonald said.

In the eyes treated with alcohol-free LASEK for near, the mean UCVA was 20/25 (range 20/20 to 20/40). Half of these eyes had a near UCVA of 20/20 or better and were not corrected for near, Dr. McDonald said. The mean UCVA at distance in these eyes was 20/40. Forty percent of these eyes achieve better than 20/40 UCVA at distance postoperatively compared with only 12% preoperatively.

At 3 months postoperatively, the LASEK-treated eyes for near had no increase in cylinder and 75% had no cylinder at all. In addition, the HOA change at 1 month was statistically significant and then returned to baseline at 3 months, except for an improvement in spherical equivalent at both 1 and 3 months.

This combination approach provides hyperopic patients with excellent UCVA at near and distance and is especially useful if more than 2 D of vision correction is needed. This bilateral treatment is beneficial in terms of HOA. However, more study is need, Dr. McDonald said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.